Freshfields announced that Sanjay Murti has joined the firm’s corporate department in New York, expanding the firm’s US M&A capabilities.
Sanjay’s practice focuses on mergers and acquisitions, shareholder activism defense, corporate governance and general corporate matters spanning many industries. He has worked on numerous M&A transactions, including high-profile sales and acquisitions of publicly traded companies, acquisitions and sales of private companies, carve-out divestitures and spin-offs, joint ventures and other strategic partnerships. He also routinely advises public companies on corporate governance and shareholder activism defense.
“Sanjay is a true legal talent,” said Freshfields’ Co-Head of US M&A Damien Zoubek. “He has an amazing combination of exceptional technical skill, great instincts, impeccable judgment and great client touch. I’ve seen first-hand Sanjay’s experience with complex, high-profile M&A transactions and I’m thrilled that he’s chosen to join Freshfields to complement our strong and growing M&A team.”
Sanjay added: “I am excited to be joining Freshfields and their M&A team at a time of such momentum and strategic focus for the firm. They have truly established themselves as a top tier destination practice, and it is the ideal place for me to grow my practice.”
Sanjay joins a team ranked the number one cross-border M&A legal advisor for 2023 by value in the year-end Bloomberg league tables. Bloomberg also ranked Freshfields eighth in the US for deal value with deals totaling $194.8 billion and in the top 10 for US announced M&A representing principals. Major deals led by our US M&A team in 2023 included Coupa’s $8 billion sale to Thoma Bravo, the Independent Directors Committee in its $12.5 billion sale of Qualtrics (also one of the largest PE buyouts of the year), Roivant on its $7.1 billion sale of Telavant to Roche; and AstraZeneca on its $1.1 billion Icosavax acquisition and $1.2 billion Gracell acquisition.
